Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11348544 | 0.74 | MMP1 (0.40) | MMP1MMP2MMP3 | |
| SCHEMBL1131219 | 0.73 | MMP1 (0.30) | MMP1MMP2MMP3 | |
| SCHEMBL4473853 | 0.72 | LAP3 (0.33) | MMP1MMP2MMP3 | |
| SCHEMBL27776117 | 0.70 | NPSR1 (0.31) | — | |
| SCHEMBL1549644 | 0.70 | GAA (0.36) | MMP1MMP2 | |
| SCHEMBL19245350 | 0.70 | TRPM8 (0.35) | MMP1MMP2MMP3 | |
| SCHEMBL4009336 | 0.70 | MMP1 (0.30) | MMP1MMP2MMP3 | |
| SCHEMBL894502 | 0.69 | LAP3 (0.32) | MMP1MMP2MMP3 | |
| SCHEMBL3175491 | 0.69 | LAP3 (0.43) | — | |
| SCHEMBL10755198 | 0.69 | LAP3 (0.33) | MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501940-B2 | Tetrahydrocinnoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20100016325-A1 | TETRAHYDROCINNOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016325-A1 | TETRAHYDROCINNOLINE DERIVATIVES | CYP27A1, CYP11B1, DHCR7 | MMP1 4502/4885MMP2 3903/4885MMP3 3279/4885 |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | MMP1 692/4885MMP2 1705/4885MMP3 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.